Octave Biotech SA is a business development and strategy consulting firm to the life sciences industry. Based in Geneva, Switzerland since 2012, our clients include small and large biotech and pharmaceutical firms, non-profit foundations, academic institutions, and investors.
Our skills and experience are at your service to help you to grow your company and find the best partner for your assets.
I am a business development executive with over twenty years of experience covering all aspects of pharmaceutical business development and alliance management. My clients are life sciences companies in Europe and the US. I am also a Board Member of Domain Therapeutics and a former Professor at the Grenoble School of Management where I taught an advanced Masters course on Business Development.
Prior to establishing my consulting practice, I spent twelve years within Index Ventures, Serono International, and Merck KGaA where, as Global Head of Licensing in neurology, dermatology, and autoimmune diseases, I managed a team of business development professionals and was instrumental in numerous product and technology transactions as well as several startup creations.
I earned a PhD in Neurobiology at the California Institute of Technology before completing a postdoctoral fellowship at the Harvard Business School. I went on to spend four years with strategic consultancy McKinsey & Company before joining the pharmaceutical industry.
Sylvie Ryckebusch
Founder
How can I help you
Develop a business
development strategy
Perform competitive analysis
Manage
due diligence process for
in-licensing or out-licensing projects
Attend partnering conferences
Identify potential partners and manage discussions
Build full risk-adjusted net present value financial models for your assets
Negotiate term sheets
and license agreements
Review agreements and
advise on contractual questions
Restructure and
amend license agreements
Values
I apply the highest ethical and professional standards to the work I do every day, while keeping my costs low so my biotech clients can focus on their core business: developing new medecines.
- BioInvent and AstraZeneca (2024)
- BioInvent and Daiichi Sankyo (2022)
- BioInvent and Merck & Co (2019-2024)
- BioInvent and Cancer Research UK (BI-1206)-2021
- BioInvent and CASI Pharmaceuticals (BI-1206)-2020
- EspeRare and Pierre Fabre (ER 004)-2020
- Dermadis and QID Pharma (DM107)-2019
- EspeRare and Edimer (ER004)-2018
- EspeRare and Merck (Rimeporide)-2013
- Merck and Ambrx (ARX-201)-2007
- Serono and ZymoGenetics (FGF18, anti-IL22RA MAb, anti-IL31 Mab)-2004
- Serono and ZymoGenetics (TACI-Ig)-2001
- Carthera and Lantheus Medical Imaging-2019
- EBA-Med and Mayo Clinic-2019
- Aleva and Dixi Medical-2019
- Aleva and Greatbatch-2016
- OTR3 and Chemineau-2016
- OTR3 and Liaoning KRS Medical Technology-2016
- Merck and Ventana-2013
- Merck and Novo Nordisk-2012
- Massachusetts Institute of Technology
- University of Bristol
- University of Erlangen
- University of Bordeaux
- University of Geneva
- University of Zurich
- Ecole Polytechnique Fédérale de Lausanne
- Karolinska Institute
- University of Lausanne
- University of Ghent
- University of Southampton
- University of Pittsburgh
- Mondor Institute
- INSERM
- BioInvent and Exelixis- 2022
- DeepCDR and Twist-2018
- Merck and Bionomics-2014
- Merck and Biopharm-2013
- Merck and Weizmann Institute-2012
- Serono and Novo Nordisk and ZymoGenetics-2006
- Serono and Dyax-2006
- Serono and Paratek Pharmaceuticals-2004
- Serono and Nautilus-2004
- Serono and ZymoGenetics 2004
- Serono and CGI Pharmaceuticals-2003
- Serono and Regeneron Pharmaceuticals-2002
- Serono and Inpharmatica-2001
- Serono and Evotec-2001
Mailing Address:
Octave Biotech SA
EPFL Innovation Park
15 avenue de Sécheron
1202 Genève
Switzerland
Telephone:
M: +41 (0)79 217 2694
Email: